We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B Turnover 46.34%
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+15.53%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$254M
AUM Growth
-$32.6M
Cap. Flow
-$20.3M
Cap. Flow %
-8%
Top 10 Hldgs %
68.51%
Holding
44
New
8
Increased
7
Reduced
10
Closed
12
Avg Time Held Equity + Options
0.5 years
Top 10 Avg Time Held Equity + Options
0.4 years
Top 20 Avg Time Held Equity + Options
0.5 years
Avg Time Held Equity only
0.6 years
Top 10 Avg Time Held Equity only
0.6 years
Top 20 Avg Time Held Equity only
0.6 years

Top Buys

Rank Stock Value
1
LKFT icon
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$9.69M
2
ITCI icon
Intra-Cellular Therapies Inc.
ITCI
+$8.8M
3
NTLA icon
Intellia Therapeutics
NTLA
+$8.27M
4
DERM icon
Dermira, Inc.
DERM
+$7.51M
5
AKAO
Achaogen Inc
AKAO
+$5.47M

Top Sells

Rank Stock Value
1
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$20.3M
2
CPXX
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
+$10.5M
3
EPZM
Epizyme, Inc
EPZM
+$9.41M
4
AIMT
Aimmune Therapeutics
AIMT
+$7.07M
5
KITE
Kite Pharma, Inc.
KITE
+$6.89M

Sector Composition

Rank Sector Weight
1 Healthcare 86.15%
2 Miscellaneous 13.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
FWP
26
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$1.53M 0.6%
12,047
-1,814
-13% -$245K
2014 Q4
6 quarters
IMGN icon
27
CALL
DELISTED
Immunogen Inc
IMGN
$922K 0.36%
299,500
– –
2016 Q1
1 quarter
AKTX icon
28
Akari Therapeutics
AKTX
$19.2M
$856K 0.34%
79
-36
-31% -$464K
2015 Q3
3 quarters
TSRO
29
DELISTED
TESARO, Inc.
TSRO
$773K 0.3%
+9,200
New +$410K
2016 Q2
0 quarters
ADXS
30
DELISTED
Advaxis Inc
ADXS
$751K 0.3%
+6,187
New +$793K
2016 Q2
0 quarters
EIGR
31
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$281K 0.11%
473
-5,845
-93% -$3.55M
2015 Q2
4 quarters
CYTK icon
32
CALL
Cytokinetics
CYTK
$8.9B
– –
-250,000
Closed -$1.76M –
LRMR icon
33
CALL
Larimar Therapeutics
LRMR
$204M
– –
-833
Closed -$67K –
DCOY icon
34
Decoy Therapeutics
DCOY
$793K
– –
-1
Closed -$6.32M –
XNTK icon
35
CALL
State Street SPDR NYSE Technology ETF
XNTK
$1.99B
– –
-297,200
Closed -$15.4M –
ATYR icon
36
aTyr Pharma
ATYR
$18.9M
– –
-5,354
Closed -$295K –
GBT
37
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-28,032
Closed -$445K –
FPRX
38
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-500,757
Closed -$20.3M –
AIMT
39
DELISTED
Aimmune Therapeutics
AIMT
– –
-521,366
Closed -$7.07M –
ONCE
40
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
– –
-8,700
Closed -$257K –
LOXO
41
DELISTED
Loxo Oncology, Inc
LOXO
– –
-150,308
Closed -$4.11M –
KITE
42
DELISTED
Kite Pharma, Inc.
KITE
– –
-150,000
Closed -$6.89M –
CPXX
43
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
– –
-950,000
Closed -$10.5M –
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q2 2016 Portfolio in Review

As of Q2 2016, EcoR1 Capital held 44 positions worth $254M, down 11% from $286M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

EcoR1 Capital withdrew a net $20.3M in Q2 2016, closing 12 positions and reducing 10 holdings. Its most notable exit was Five Prime Therapeutics, Inc., an estimated $20.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 76% a quarter earlier, followed by Miscellaneous.

Against the trend, EcoR1 Capital opened a new position in Intra-Cellular Therapies Inc. worth $9.51M.

  • EcoR1 Capital's largest Q2 2016 buy was Intra-Cellular Therapies Inc.: 244,950 shares worth $9.51M.
  • EcoR1 Capital added most to Lakefront Biotherapeutics American Depositary Shares in Q2 2016, an estimated $9.69M increase.
  • EcoR1 Capital's biggest Q2 2016 reduction was Epizyme, Inc, cutting an estimated $9.41M.
  • EcoR1 Capital fully exited Five Prime Therapeutics, Inc. in Q2 2016, selling an estimated $20.3M.
  • EcoR1 Capital's ten largest holdings make up 69% of its $254M portfolio in Q2 2016.
  • EcoR1 Capital opened 8 new positions and closed 12 in Q2 2016.
  • EcoR1 Capital's portfolio value fell 11% quarter-over-quarter to $254M.

Based on EcoR1 Capital's 13F filing for Q2 2016, filed 15 Aug 2016.